Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?

Cancer Treatment Reviews

Volumn 38, Issue 1, 2012, Pages 54-62

  Meza Junco, Judith ^a   Montano Loza, Aldo J ^b   Liu, David M ^c,d   Sawyer, Michael B ^a   Bain, Vincent G ^b   Ma, Mang ^b   Owen, Richard ^e  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Drug eluting bead; Hepatocellular carcinoma; Percutaneous ethanol injection; Radiofrequency ablation; Transarterial chemoembolization; Transarterial radioembolization

Indexed keywords

ALCOHOL; CHLOROTRIANISENE; DOXORUBICIN;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE SEVERITY; LIVER CELL CARCINOMA; MEDLINE; RADIOFREQUENCY ABLATION; REVIEW;

ABLATION TECHNIQUES; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MICROSPHERES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84855930184     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.002     Document Type: Review

References (63)

1. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19:3-23.
2. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract Res Clin Gastroenterol 2005, 21:161-173.
3. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl 1):S20-S37.
4. Han K.H., Kim J.K. Liver cancer in Korea. Hepatol Research 2007, 37:106-109.
5. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430.
6. Bruix J., Sherman M. Management of Hepatocellular Carcinoma. Hepatology 2005, 42:1208-1236.
7. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
8. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Panel of experts in HCC-design clinical trials design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
9. Ibrahim S.M., Lewandowski R.J., Sato K.T., et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008, 14:1664-1669.
10. Kettenbach J., Stadler A., Katzler I.V., et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol 2008, 31:468-476.
11. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2002, 106:1883-1892.
12. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104:514-524.
13. Bouza C., López-Cuadrado T., Alcázar R., et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009, 11(9):31.
14. Kong W.T., Zhang W.W., Qiu Y.D., et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009, 15:2651-2656.
15. McGhana J.P., Dodd G.D. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol 2001, 176:3-16.
16. Livraghi T., Solbiati L., Meloni M.F., Gazelle G.S., Halpern E.F., Goldberg S.N. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226:441-451.
17. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004, 127:1714-1723.
18. Giorgio A., Tarantino L., de Stefano G., Coppola C., Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. AJR Am J Roentgenol 2005, 184:207-211.
19. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation vs percutaneous ethanol injection. Radiology 2003, 228:235-240.
20. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
21. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54:1151-1156.
22. Brunello F., Veltri A., Crucci P., et al. Radiofrequency ablation vs ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008, 43:727-735.
23. Brown D.B., Gould J.E., Gervais D.A., et al. Society of interventional radiology technology assessment committee and the international working group on image-guided tumor ablation transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009, 20:S425-S434.
24. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
25. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1):6-25.
26. Castells A., Bruix J., Ayuso C., et al. Transarterial embolization for hepatocellular carcinoma antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995, 22:410-415.
27. Shelgikar C.S., Loehle J., Scoggins C.R., et al. Empiric antibiotics for transarterial embolization in hepatocellular carcinoma: indicated?. J Surg Res 2009 Jan, 151121-151124.
28. Kim W., Clark T.W., Baum R.A., Soulen M.C. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001, 12:965-968.
29. Varela M., Real M.I., Burrel M., et al. Chemoembolisation of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
30. Poon R.T., Tso W.K., Pang R.W., et al. A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007, 5:1100-1108.
31. Malagari K., Chatzimichael K., Alexopoulou E., et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008, 31:269-280.
32. Sadick M., Haas S., Loehr M., et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie 2010, 33:31-37.
33. Lammer J., Malagari K., Vogl T., et al. On behalf of the PRECISION V investigators prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52.
34. Vogl T.G., Lee C., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. J Clin Oncol 2010, 28(suppl):14660A.
35. Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997, 26:1156-1161.
36. Vente M.A., Wondergem M., van der Tweel I., et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19:951-959.
37. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
38. Kulik L.M., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47:71-81.
39. Salem R., Riaz A., Lewandowski R., et al. Comparative effectiveness of radioembolization, the standard of care for hepatocellular carcinoma: is a randomized survival study feasible?. J Clin Oncol 2010, 28:4045A.
40. Koda M., Murawaki Y., Mitsuda A., et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001, 92:1516-1524.
41. Bartolozzi C., Lencioni R., Caramella D., et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995, 197:812-818.
42. Becker G., Soezgen T., Olschewski M., et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005, 11:6104-6109.
43. Akamatsu M., Yoshida H., Obi S., et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004, 24:625-629.
44. Marelli L., Stigliano R., Triantos C., et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006, 32:594-606.
45. Llovet J.M., Ricci S., Mazzaferro V.N., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
46. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
47. Chow P.K., Poon D., Win K.M., et al. Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: the Asia-Pacific hepatocellular carcinoma trials group protocol 05 (AHCC05). J Clin Oncol 2010, 28(suppl):4072A.
48. Chung Y., Kim B., Chen C., et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis. J Clin Oncol 2010, 28(suppl):4026A.
49. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
50. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication 48. Geneva Switzerland: World Health Organization; 1979.
51. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
52. Therasse P., Eisenhauer E.A., Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006, 42:1031-1039.
53. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430.
54. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60.
55. Riaz A., Ryu R.K., Kulik L.M., et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009, 27:5734-5742.
56. Lin D.Y., Liaw Y.F., Lee T.Y., et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988, 94:453-456.
57. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990, 11:181-184.
58. Group d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
59. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998, 27:1578-1583.
60. Pelletier G., Ducreux M., Gay F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998, 29:129-134.
61. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
62. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
63. Sangro S., Carpanese L., Cianni R., et al. European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. J Clin Oncol 2010, 28(suppl):4027A.